Accreditation/Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this live activity for a maximum of 23.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTINUING EDUCATION CREDIT (Pharmacists, Nurses, Nurse Practitioners, and Physician Assistants):You will receive a certificate of attendance for the CME-certified sessions (those designated for AMA/PRA Category 1 Credits™) which may be submitted to state licensing boards for determination of credit reciprocity (conversion to CEUs).

Overview

State-of-the-art cancer care continues to evolve due to advances in all aspects of patient care - including diagnosis, and personalized treatment and management. Through the incorporation of novel diagnostics, systemic therapies, molecular targeted therapies, immunotherapies, and other biotechnological strategies into treatment paradigms, patient outcomes continue to improve along the cancer continuum. The annual CFS™ Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®, has brought together over 2,000 oncologists, hematologists, radiation oncologists, immunologists, oncology nurses, nurse practitioners, physician assistants, and case managers each year for 32 years, with the aim of educating these disciplines on state-of-the-art treatments across solid and hematologic malignancies and diverse clinical scenarios. At the 33rd Annual CFS™ Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®, our outstanding faculty of leading clinical innovators in virtually every tumor subspecialty will continue to provide expert insights on new developments in cancer therapeutics, and provide oncology professionals with the opportunity to learn about new compounds, novel approaches to diagnosis and treatment with currently available agents, ongoing clinical trials, and emerging developments that define current progress aimed at the goal of control and cure of cancer.

Target Audience

This educational program is directed toward oncologists and hematologists interested in the treatment of patients with cancer. Radiotherapists, immunologists, fellows, nurse practitioners, nurses, physician assistants, researchers, case managers, and other health care professionals interested in the treatment of cancer are also invited to attend.